


Product datasheet

Anti-CCM2 antibody ab53557

1 Image

Overview

Product name	Anti-CCM2 antibody
Description	Goat polyclonal to CCM2
Specificity	This antibody is expected to recognize both reported isoforms (NP_001025006.1 and NP_113631.1).
Tested applications	Suitable for: WB
Species reactivity	Reacts with: Human Predicted to work with: Mouse, Rat, Cow, Dog 
Immunogen	Synthetic peptide: C-KGEKSRDKKAHEK , corresponding to internal sequence amino acids 23-35 of Human CCM2 Run BLAST with Run BLAST with
Positive control	Human heart lysate.

Properties

Form	Liquid
Storage instructions	Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Storage buffer	Preservative: 0.02% Sodium Azide Constituents: 0.5% BSA, Tris saline, pH 7.3
Purity	Immunogen affinity purified
Purification notes	Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
Clonality	Polyclonal
Isotype	IgG

Applications

Our [Abpromise guarantee](#) covers the use of **ab53557** in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application	Abreviews	Notes
-------------	-----------	-------

WB

Application notes

Peptide ELISA: antibody detection limit dilution 1:128,000.

WB: Use at a concentration of 0.03 - 0.1 µg/ml. Detects a band of approximately 49 kDa (predicted molecular weight: 49 kDa).

Not yet tested in other applications.

Optimal dilutions/concentrations should be determined by the end user.

Target

Function

May function as a scaffold protein for MAP2K3-MAP3K3 signaling. Seems to play a major role in the modulation of MAP3K3-dependent p38 activation induced by hyperosmotic shock.

Involvement in disease

Defects in CCM2 are the cause of cerebral cavernous malformations type 2 (CCM2) [MIM:603284]. Cerebral cavernous malformations (CCMs) are congenital vascular anomalies of the central nervous system that can result in hemorrhagic stroke, seizures, recurrent headaches, and focal neurologic deficits. CCMs have an incidence of 0.1%-0.5% in the general population and are usually present clinically during the 3rd to 5th decades of life. The lesions are characterized by grossly enlarged blood vessels consisting of a single layer of endothelium and without any intervening neural tissue, ranging in diameter from a few millimeters to several centimeters.


Sequence similarities

Contains 1 PID domain.

Cellular localization

Cytoplasm.

Images



Anti-CCM2 antibody (ab53557) at 0.03 µg/ml
+ Human Heart lysate (35µg protein in RIPA
buffer)

Predicted band size : 49 kDa

Observed band size : 49 kDa

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Our Abpromise to you: Quality guaranteed and expert technical support

- Replacement or refund for products not performing as stated on the datasheet
- Valid for 12 months from date of delivery
- Response to your inquiry within 24 hours

- We provide support in Chinese, English, French, German, Japanese and Spanish
- Extensive multi-media technical resources to help you
- We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit <http://www.abcam.com/abpromise> or contact our technical team.

Terms and conditions

- Guarantee only valid for products bought direct from Abcam or one of our authorized distributors